These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 23124417)
1. Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer. Lu L; Zhu G; Zhang C; Deng Q; Katsaros D; Mayne ST; Risch HA; Mu L; Canuto EM; Gregori G; Benedetto C; Yu H Breast Cancer Res Treat; 2012 Dec; 136(3):875-83. PubMed ID: 23124417 [TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer. Sørensen KP; Thomassen M; Tan Q; Bak M; Cold S; Burton M; Larsen MJ; Kruse TA Breast Cancer Res Treat; 2013 Dec; 142(3):529-36. PubMed ID: 24258260 [TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Kogo R; Shimamura T; Mimori K; Kawahara K; Imoto S; Sudo T; Tanaka F; Shibata K; Suzuki A; Komune S; Miyano S; Mori M Cancer Res; 2011 Oct; 71(20):6320-6. PubMed ID: 21862635 [TBL] [Abstract][Full Text] [Related]
4. HOXD13 methylation status is a prognostic indicator in breast cancer. Zhong Z; Shan M; Wang J; Liu T; Xia B; Niu M; Ren Y; Pang D Int J Clin Exp Pathol; 2015; 8(9):10716-24. PubMed ID: 26617782 [TBL] [Abstract][Full Text] [Related]
5. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312 [TBL] [Abstract][Full Text] [Related]
6. Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer. Nakagawa T; Endo H; Yokoyama M; Abe J; Tamai K; Tanaka N; Sato I; Takahashi S; Kondo T; Satoh K Biochem Biophys Res Commun; 2013 Jun; 436(2):319-24. PubMed ID: 23743197 [TBL] [Abstract][Full Text] [Related]
7. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823 [TBL] [Abstract][Full Text] [Related]
8. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955 [TBL] [Abstract][Full Text] [Related]
9. Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Arai T; Miyoshi Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S Breast Cancer Res Treat; 2006 Nov; 100(2):169-76. PubMed ID: 16791478 [TBL] [Abstract][Full Text] [Related]
10. The long non-coding RNA HOTAIR is upregulated in endometrial carcinoma and correlates with poor prognosis. He X; Bao W; Li X; Chen Z; Che Q; Wang H; Wan XP Int J Mol Med; 2014 Feb; 33(2):325-32. PubMed ID: 24285342 [TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023 [TBL] [Abstract][Full Text] [Related]
12. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Martins AT; Monteiro P; Ramalho-Carvalho J; Costa VL; Dinis-Ribeiro M; Leal C; Henrique R; Jerónimo C Breast Cancer Res Treat; 2011 Aug; 129(1):1-9. PubMed ID: 20842524 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789 [TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230 [TBL] [Abstract][Full Text] [Related]
15. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma. Eggers H; Steffens S; Grosshennig A; Becker JU; Hennenlotter J; Stenzl A; Merseburger AS; Kuczyk MA; Serth J Int J Oncol; 2012 May; 40(5):1650-8. PubMed ID: 22327210 [TBL] [Abstract][Full Text] [Related]
16. Let-7a regulation of insulin-like growth factors in breast cancer. Lu L; Katsaros D; Zhu Y; Hoffman A; Luca S; Marion CE; Mu L; Risch H; Yu H Breast Cancer Res Treat; 2011 Apr; 126(3):687-94. PubMed ID: 20848182 [TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of HOTAIR expression is restricted to ER-negative breast cancers. Gökmen-Polar Y; Vladislav IT; Neelamraju Y; Janga SC; Badve S Sci Rep; 2015 Mar; 5():8765. PubMed ID: 25739705 [TBL] [Abstract][Full Text] [Related]
18. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer. Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007 [TBL] [Abstract][Full Text] [Related]
19. Role of HOTAIR in the diagnosis and prognosis of acute leukemia. Zhang YY; Huang SH; Zhou HR; Chen CJ; Tian LH; Shen JZ Oncol Rep; 2016 Dec; 36(6):3113-3122. PubMed ID: 27748863 [TBL] [Abstract][Full Text] [Related]
20. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Yu H; Levesque MA; Clark GM; Diamandis EP Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]